Horizon Europe 2022 calls
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
Horizon Europe 2022 calls
HORIZON-HLTH-2022-STAYHLTH-01-04-two-stage: Trustworthy artificial intelligence
(AI) tools to predict the risk of chronic non-communicable diseases and/or their progression
Develop and test AI tools for assessing and predicting the risk of developing a disease and/or the risk of disease progression once it is diagnosed, taking into
account the individuals’ (or groups) genotypes, phenotypes, life-style, occupational/environmental stressors and/or socio-economic and behavioural characteristics,
as necessary.
EXPECTED OUTCOMES
• Clinical researchers use effective health data integration solutions for the classification of the clinical phenotypes.
• Researchers and/or health care professionals use robust and validated data-driven computational tools to successfully stratify patients.
• Regulatory bodies approve computer-aided patient stratification strategies to enable personalised diagnosis and/or personalised
therapy strategies.
• Health care professionals adopt evidence-based guidelines for stratification-based patient management superior to the standard-of-
care.
SCOPE
• Leverage existing high-quality health- progression and in particular their health outcomes and enabling
relevant data from multiple sources accuracy, reliability, reproducibility and personalised prevention strategies.
and/or generation of new high-quality generalisability. Proposals should assess
health data necessary for the rigorous the possible inherent bias introduced to • Implement proof of concept and/or
development of the AI disease-risk tools the AI tools originating from the data feasibility studies to validate the AI tools
quality used for their development. for risk assessment of disease and/or
• Develop the adequate performance disease progression in a relevant end-
metrics to assess the technical robustness • Develop the criteria to assess the users environment and/or real-world
of the developed AI tools for risk effectiveness of the AI tools for disease setting and assess their performance in
assessment of disease and/or disease risk assessment in terms of improving comparison to the standard-of-care
Opening date: 06 Oct 2021
Indicative budget: 60M € Type of action: Research
Deadline(s): 01 Feb 2022 (1st stage)
EU contribution per project: 6M € and Innovation Actions
06 Sept 2022 (2nd stage)HORIZON-HLTH-2022-STAYHLTH-01-05-two-stage: Prevention of obesity
throughout the life course
Proposals should aim to develop scientifically robust and transparent methodologies, building on achievements from previous research activities.
EXPECTED OUTCOMES
• Researchers, developers of medical • Have access to, adopt and implement cost data related to the prevention and
interventions, and health care evidence-based clinical guidelines, best treatment of overweight/obesity and its
professionals have a much better practices, coordinated, pan-European, co-morbidities at population level across
understanding of basic biological multidisciplinary preventive strategies, European regions and countries.
pathways (genetic and epigenetic policy recommendations and/or new
blueprints) conferring susceptibility to and policies to fight overweight/obesity and • Adopt and implement tailor-made
protecting against overweight/obesity their co-morbidities throughout the life prevention campaigns to tackle
course. overweight/obesity, Citizens have access
• Health care professionals, national / to and make use of new tools and services
regional / local public authorities and • Have access to and make use of a robust to make informed decisions about lifestyle
other relevant actors: outcome framework and tool-kit for choices that will prevent them from
standardised collection of economic and becoming overweight/obese.
SCOPE
• A comprehensive understanding of environmental interventions aiming at relationship between the risk for
biological pathways conferring obesity prevention and tailored to specific overweight/obesity and the biology of
susceptibility to and protecting against target populations. obesity, lifestyle habits, exposures,
uncontrolled “weight gain". susceptibility to co-morbidities and/or all
• Mapping existing implementation of their combinations
• Identification of socio-economic and research activities to prevent
lifestyle factors influencing consumer overweight/obesity, outcome analyses • Developing recommendations and
behaviour and their association to and identification of best practices. guidelines for what constitutes an
overweight/obesity prevention. appropriate healthy diet for different age
• Conducting a thorough meta-review of and health groups
• Identification of pre-obesity biomarkers information from available scientific
and their association to lifestyle and literature and identification of the
Opening date: 06 Oct 2021
Indicative budget: 60M € Type of action: Research
Deadline(s): 01 Feb 2022 (1st stage)
EU contribution per project: 10M € and Innovation Actions
06 Sept 2022 (2nd stage)HORIZON-HLTH-2021-CARE-05-02: Data-driven decision-support tools for better
health care delivery and policy-making with a focus on cancer
Proposals should adopt a patient-centred approach that empowers patients, promotes a culture of dialogue and openness between citizens/patients,
caregivers, health care providers and other relevant stakeholders, and unleashes the potential for social innovation.
EXPECTED OUTCOMES
• Health care organisations and policymakers adopt robust and • Health system owners are provided with evidence-based
transparent modelling (including data collection, storage and participative decision-making processes that take into
analysis), planning algorithms and artificial intelligence (AI) consideration all relevant values, needs and perspectives,
solutions in support of health care decision-making processes; enabling to deliver health care services to patients in the most
suitable and efficient manner;
• Health care providers, caregivers (formal and informal), citizens,
and other relevant stakeholders take better informed decisions • Policymakers access evidence-based, interoperable decision
about their health or the health of persons they are responsible support tools for public health policy-making and health care
for and/or about the organisation of the health care service or delivery.
system they are involved in or in charge of;
SCOPE
• The development of data-driven,
evidence-informed decisions on cancer care assessment of outputs from end-user
interactive policy and visualisation tools delivery processes such as logistics planning involvements
(i.e. through creation of digital twins/virtual
and management, capacity, utilisation of
models) bringing novel insights on health services and allocation of resources • The development of data-driven solutions
populations, systems and services as a and infrastructures (i.e. human resources, empowering citizens' and cancer patients'
whole, to help policymakers make data- health goods, etc.), and availability of and interaction with the health care systems,
driven decisions access to health care technologies and including feedback mechanisms, guidance
interventions on health care pathways and on managing
• The development of data-driven solutions health care data, supporting patients in
(i.e scenario-building tools and models) • The development of digital toolkits and making health care decisions and treatment
helping health care organisations take indicators to improve the reporting and adherence
Opening date: 22 Jun 2021 Indicative budget: 40M € Type of action: Research
Deadline(s): 21 Sept 2021 EU contribution per project: 10M € Innovation ActionsHORIZON-HLTH-2022-STAYHLTH-02-01-single-stage: Personalised blueprint of
chronic inflammation in health-to-disease transition
Develop and implement data-driven, personalised approaches to identify the drivers of chronic inflammation that may determine the
transition from health to pre-symptomatic and early stages of chronic diseases/disorders
EXPECTED OUTCOMES
• Researchers and medical professionals health status, establishing personalised • Citizens are better informed to actively
understand the chronic inflammation prevention measures and improving the manage their own health, have the tools
factors triggering the health-to-disease health outcomes for citizens. to maintain their healthy status, improve
transition and subsequently provide their health and reduce their risk for
optimal counselling to citizens for • Health care professionals have the developing chronic diseases.
improving their health. scientific evidence and understanding of
health-to-disease transition to develop
• Health care professionals have access to and use improved guidelines for
and employ objective health indicators of personalised prevention strategies to
chronic inflammation for monitoring the tackle chronic diseases.
SCOPE
• Integrate state-of-the-art knowledge and human biology and physiology underlying and to identify objective indicators of
data from suitable human studies to chronic inflammation in connection to the chronic inflammation correlative to the
identify actionable factors linking chronictissues/organ dysregulation, organ cross- health-to-disease transition
systemic and/or local inflammation to the talk and homeostasis breakdown
health-to-disease transition. triggering the health-to-disease transition. • Test suitable interventions with the aim
to demonstrate the reduction and/or
• Identify biomarkers and other health • Develop and deploy robust sensors, reversion of the pre-disease state linked
indicators linked to the health-to-disease devices and/or mobile apps and other to chronic systemic and/or local
transition. innovative technologies to monitor inflammation.
dynamically the individual’s health status
• Understand at the systems-level the
Opening date: 06 Oct 2021 Indicative budget: 50M € Type of action: Research
Deadline(s): 21 April 2022 EU contribution per project: 7M € and Innovation ActionsHORIZON-HLTH-2022-IND-13-02: Scaling up multi-party computation, data
anonymisation techniques, and synthetic data generation
The proposals are expected to foster the development of secure, interoperable, transparent -and therefore trustable - cross-border health data hubs
that can facilitate the provision of the required testing environments for innovators
EXPECTED OUTCOMES
• The EU contributes strongly to global standards for health data • Cross-border health data hubs further facilitate the innovation
through enhancement of common European standards for health process by providing secure, trustable testing environments for
data (including medical imaging data) by researchers and innovators.
innovators. Researchers and innovators contribute to GDPR
compliant guidelines and rules for data anonymisation. • Clinicians, patients and individuals use a larger variety of high
quality data tools and services for wellbeing, prevention, diagnosis,
• Innovators have access to advanced secure data processing tools treatment and follow-up of care.
to test and develop robust data-driven digital solutions and
services in response to the needs of researchers, clinicians and • Researchers and innovators have more opportunities for testing
health systems at large. and developing GDPR compliant data driven solutions based on
actual needs of the health care environments.
SCOPE
• Consolidate and scale up multi-party • Advance the state-of-the-art of de- on demand for specific use cases.
computation and data anonymisation identification techniques, to tackle the
techniques and synthetic data generation challenge of anonymised datasets that can • Widen the basis for GDPR-compliant
to support health technology providers, in be traced back to individuals. research and innovation on health data.
particular SMEs.
• Develop innovative anonymisation • Ensure wide uptake and scalability of the
• Support the development of innovative techniques demonstrating that effective methodologies and tools developed,
unbiased AI based and distributed tools, data quality and usefulness can be promote high standards of transparency
technologies and digital solutions for the preserved without compromising privacy. and openness, going well beyond
benefit of researchers, patients and documentation and extending to aspects
providers of health services, while • Explore and develop further the techniques such as assumptions, architecture, code
maintaining a high level of data privacy. of creating synthetic data, also dynamically and any underlying data.
Opening date: 06 Oct 2021 Indicative budget: 30M € Type of action: Research
Deadline(s): 21 April 2022 EU contribution per project: 7M € and Innovation ActionsHORIZON-HLTH-2022-DISEASE-07-02: Pandemic preparedness
A key component for the European Health Union will be the establishment of the Health Emergency Preparedness and Response Authority (HERA) for
which the Commission will put forward a legislative proposal by the end of 2021
EXPECTED OUTCOMES
• The scientific community has better understanding of the biology of the pathogens (virus, bacteria etc.), its transmission, its interaction
with humans, animals and plants, in particular in view of emerging threats to human health, such as infectious diseases and anti-
microbial resistance.
• Health care providers and practitioners have access to and use appropriate medical countermeasures, e.g. vaccines, diagnostics,
therapeutics and digital solutions.
• Health authorities have the evidence-base and tools for better public health measures.
SCOPE
• This topic aims to contribute and complement both of these initiatives, notably by addressing priority research and innovation gaps
also identified by Member States and that would contribute and support the establishment and work of a potential future Health
Emergency Preparedness and Response Authority (HERA).
• Research focussing on ‘pathogen X’ from threat assessment, horizon scanning for the identification of potential medical
countermeasures and innovative technologies, including the development of standardised research protocols would be in the scope of
this topic.
Opening date: 12 Jan 2022 Indicative budget: 10M € Type of action: Research
Deadline(s): 21 April 2022 EU contribution per project: 3M € and Innovation ActionsHORIZON-HLTH-2022-TOOL-11-01: Optimising effectiveness in patients of existing
prescription drugs for major diseases (except cancer) with the use of biomarkers
The applicants should consider existing guidelines, standards and regulations, as appropriate. Synergies with relevant European Research
Infrastructures are encouraged.
EXPECTED OUTCOMES
• Diagnostics industries move towards market approval for companion diagnostics.
• Regulatory authorities approve companion diagnostics and make recommendations for the prescription of existing drugs.
• Health care providers use biomarkers with existing pharmaceuticals to treat more efficiently and cost-effectively patients, with less
adverse effects.
SCOPE
• The applicants should perform the clinical the right dose and the right time, for major diseases and conditions,
validation of qualified biomarkers (not according to the concept of personalised including but not limited to cardiovascular
limited to molecular biomarkers) that will medicine, taking into account, among diseases.
enable the identification of appropriate others, differences of sex, age, ethnicity
patients to ensure an effective and and gender identity • A condition is that preliminary studies or
efficient use of existing pharmaceuticals in publications have demonstrated that the
the treatment of major diseases and • This topic refers to medicines that are pharmaceuticals considered are efficient
conditions already on the market and not to the in less than 50% of the population treated
validation of biomarkers for the
• The relevant biomarkers should allow development of new medicinal products. • This topic excludes cancer and rare
providing the right medicinal product, at It addresses broadly prescribed medicines disease treatments
Opening date: 06 Oct 2021 Indicative budget: 60M € Type of action: Research
Deadline(s): 21 April 2022 EU contribution per project: 6M € and Innovation ActionsYou can also read
